Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 46.0% in November

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 11,400 shares, a decline of 46.0% from the October 31st total of 21,100 shares. Based on an average daily trading volume, of 336,800 shares, the short-interest ratio is currently 0.0 days. Currently, 2.1% of the company’s stock are short sold.

Bluejay Diagnostics Price Performance

NASDAQ BJDX traded up $0.02 on Friday, hitting $3.50. 8,300 shares of the stock were exchanged, compared to its average volume of 103,749. The company has a market capitalization of $1.89 million, a PE ratio of 0.00 and a beta of 0.73. The business’s fifty day moving average is $5.11 and its 200 day moving average is $52.98. Bluejay Diagnostics has a 52 week low of $3.03 and a 52 week high of $1,564.00.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. CVI Holdings LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned about 19.69% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.